[go: up one dir, main page]

MX376652B - Método para determinar la eficacia de una terapia con fármacos de direccionamiento a glipicano 3 (gpc3) contra cáncer. - Google Patents

Método para determinar la eficacia de una terapia con fármacos de direccionamiento a glipicano 3 (gpc3) contra cáncer.

Info

Publication number
MX376652B
MX376652B MX2015007714A MX2015007714A MX376652B MX 376652 B MX376652 B MX 376652B MX 2015007714 A MX2015007714 A MX 2015007714A MX 2015007714 A MX2015007714 A MX 2015007714A MX 376652 B MX376652 B MX 376652B
Authority
MX
Mexico
Prior art keywords
gpc3
therapeutic agent
targeted therapeutic
agent therapy
patient
Prior art date
Application number
MX2015007714A
Other languages
English (en)
Other versions
MX2015007714A (es
Inventor
Jun Amano
Mikiko Nakamura
Toshihiko Ohtomo
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2015007714A publication Critical patent/MX2015007714A/es
Publication of MX376652B publication Critical patent/MX376652B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a un método para determinar la eficacia de la terapia con fármacos de direccionamiento a GPC3 contra el cáncer en un paciente antes del comienzo de la terapia con fármacos de direccionamiento a GPC3 para un paciente o para determinar la continuación de la terapia con fármacos de direccionamiento a GPC3 para un paciente, que incluye el monitoreo de una concentración de GPC3 libre en una muestra biológica aislada del paciente antes del comienzo de la terapia con fármacos de direccionamiento a GPC3 y/o en el paciente tratado con la terapia con fármacos de direccionamiento a GPC3, en donde cuando la concentración de GPC3 libre es un valor predeterminado, se determina la eficacia de la terapia con fármacos de direccionamiento a GPC3 o se determina la continuación de la terapia con fármacos de direccionamiento a GPC3. La presente invención describe además un fármaco de direccionamiento a GPC3 o una preparación que será administrada a su vez a un paciente para quien se ha determinado la eficacia de la terapia con fármacos de direccionamiento a GPC3 o se ha determinado la continuación de la terapia con fármacos de direccionamiento a GPC3.
MX2015007714A 2012-12-21 2013-12-24 Método para determinar la eficacia de una terapia con fármacos de direccionamiento a glipicano 3 (gpc3) contra cáncer. MX376652B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012280304 2012-12-21
PCT/JP2013/007529 WO2014097648A1 (ja) 2012-12-21 2013-12-24 Gpc3標的治療剤療法が有効である患者に投与されるgpc3標的治療剤

Publications (2)

Publication Number Publication Date
MX2015007714A MX2015007714A (es) 2015-09-07
MX376652B true MX376652B (es) 2025-03-07

Family

ID=50978006

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007714A MX376652B (es) 2012-12-21 2013-12-24 Método para determinar la eficacia de una terapia con fármacos de direccionamiento a glipicano 3 (gpc3) contra cáncer.

Country Status (14)

Country Link
US (2) US10782300B2 (es)
EP (1) EP2937697B1 (es)
JP (2) JP6359461B2 (es)
KR (1) KR102216345B1 (es)
CN (2) CN104871003B (es)
AR (1) AR094269A1 (es)
AU (1) AU2013365430B2 (es)
CA (1) CA2895333A1 (es)
IL (1) IL239488B (es)
MX (1) MX376652B (es)
RU (1) RU2707882C2 (es)
SG (2) SG11201504604WA (es)
TW (1) TWI693073B (es)
WO (1) WO2014097648A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
US11760807B2 (en) 2014-05-08 2023-09-19 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
DK3205661T3 (da) 2014-10-07 2021-08-02 Cytlimic Inc Hsp70-afledt immunitetsinducerende peptid
TW201636358A (zh) * 2014-12-09 2016-10-16 腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｇｐｃ３抗原決定位胜肽及含此之疫苗
CN107428815B (zh) * 2015-03-09 2021-07-09 Cytlimic公司 源于gpc3的肽、使用其的用于治疗或预防癌症的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法
DK3281641T3 (da) 2015-04-07 2021-01-18 Cytlimic Inc Adjuvans til cancervacciner
EP3318879B1 (en) * 2015-07-01 2020-10-21 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting therapeutic agent which is administered to patient for whom the gpc3-targeting therapeutic agent is effective
CN106397593B (zh) * 2015-08-03 2019-09-10 科济生物医药（上海）有限公司 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用
EP3153230A1 (en) * 2015-10-08 2017-04-12 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin A method for the production of poly(methyl methacrylate) (pmma) membranes and uses thereof
KR101796688B1 (ko) * 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
CN105759051B (zh) * 2016-02-25 2018-12-18 广州科方生物技术股份有限公司 一种磷脂酰肌醇蛋白聚糖-3的定量分析试剂盒及其制备方法
KR102018774B1 (ko) * 2016-03-07 2019-09-04 포항공과대학교 산학협력단 Glypican-3에 선택적으로 결합하는 압타머 및 이의 용도
WO2017159699A1 (en) 2016-03-15 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
WO2018070069A1 (ja) 2016-10-11 2018-04-19 サイトリミック株式会社 医薬
KR102564097B1 (ko) 2017-01-10 2023-08-04 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 항 gpc3 항체
BR112019025612A2 (pt) * 2017-06-05 2020-06-16 Janssen Biotech, Inc. Métodos de manipular carga de superfície para a produção de anticorpos biespecíficos
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
WO2020089769A1 (en) * 2018-10-29 2020-05-07 Janssen Biotech, Inc. Antibodies specifically binding hla-dr/colii_259 complex and their uses
KR102154683B1 (ko) * 2019-11-08 2020-09-11 주식회사 압타머사이언스 글리피칸-3 특이적 변형 압타머 및 이의 용도
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CN113444179B (zh) * 2020-03-26 2022-09-02 苏州普乐康医药科技有限公司 一种抗gpc3抗体和包含该抗体的药物组合物
CN117062834A (zh) * 2021-02-10 2023-11-14 先声再明医药有限公司 Gpc3人源化抗体及其应用
AU2022237618A1 (en) 2021-03-17 2023-10-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
WO2022268196A1 (zh) * 2021-06-25 2022-12-29 天辰生物医药(苏州)有限公司 靶向gpc3的抗原结合蛋白
AU2022350496A1 (en) * 2021-09-22 2024-04-04 Board Of Regents, The University Of Texas System Quantitative magnetic resonance imaging and tumor forecasting
CN113817055B (zh) * 2021-10-27 2023-04-18 福州迈新生物技术开发有限公司 抗Actin蛋白单克隆抗体、细胞系及其应用
JP2024545363A (ja) 2021-11-16 2024-12-05 ソティオ・バイオテック・インコーポレイテッド 粘液型／円形細胞型脂肪肉腫患者の治療
US20250195681A1 (en) * 2022-03-18 2025-06-19 Duality Biologics (Suzhou) Co., Ltd. Anti-gpc3 antibody drug conjugate and use thereof
CN120051491A (zh) 2022-11-01 2025-05-27 上海齐鲁制药研究中心有限公司 一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用
EP4611811A1 (en) * 2022-11-04 2025-09-10 Foundation Medicine, Inc. Composite immune biomarkers and uses thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
WO1996004925A1 (en) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ATE412433T1 (de) 1999-02-12 2008-11-15 Scripps Research Inst Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
HU231090B1 (hu) 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
US6436411B1 (en) * 2000-10-23 2002-08-20 The Center For The Improvement Of Human Functioning, Int'l., Inc. Cancer treatment method
WO2002040545A2 (en) 2000-11-17 2002-05-23 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
JP2005500018A (ja) 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
PT2208784E (pt) 2001-06-22 2013-04-03 Chugai Pharmaceutical Co Ltd Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3
EP3960855A1 (en) 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
WO2004022597A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
NZ536521A (en) 2002-05-23 2006-04-28 Sunnybrook And Womenaes Colleg Diagnosis of hepatocellular carcinoma
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
AU2002328429A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
PL222220B1 (pl) 2003-01-22 2016-07-29 Glycart Biotechnology Ag Komórka gospodarza i sposób wytwarzania polipeptydu w komórce gospodarza
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JPWO2005023301A1 (ja) 2003-09-04 2006-11-02 中外製薬株式会社 胆管癌治療剤および検出薬
DE602005015542D1 (de) 2004-01-12 2009-09-03 Applied Molecular Evolution Varianten der fc-region
EP1742061A4 (en) * 2004-04-28 2007-11-21 Perseus Proteomics Inc MEDIUM FOR PREDICTING AND EVALUATING THE REACTION OF LIVER CANCER AFTER TREATMENT
JP4331227B2 (ja) * 2004-07-09 2009-09-16 中外製薬株式会社 抗グリピカン３抗体
EP2216046B1 (en) 2004-07-09 2014-03-12 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
CN101001873B (zh) 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Fc区变体
EP1784424A4 (en) 2004-08-16 2009-03-18 Medimmune Inc EPH RECEPTOR BINDING FC VARIANTS HAVING CELLULAR CELLULAR ACTIVITY DEPENDENT ANTIBODIES
US20060067930A1 (en) 2004-08-19 2006-03-30 Genentech, Inc. Polypeptide variants with altered effector function
US7871613B2 (en) * 2004-08-24 2011-01-18 Chugai Seiyaku Kabushiki Kaisha Adjuvant therapy with the use of anti-glypican 3 antibody
WO2006038588A1 (ja) 2004-10-05 2006-04-13 Perseus Proteomics Inc. 肝炎重篤化のモニター薬
RU2451030C2 (ru) 2004-10-26 2012-05-20 Чугаи Сейяку Кабусики Кайся Анти-глипикан 3-антитело, имеющее модифицированную сахарную цепь
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
EP1829961A4 (en) 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd PROCESS FOR PREPARING ANTIBODY USING A CELL WHOSE FUCOSE CARRIER FUNCTION IS INHIBITED
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
US8309690B2 (en) 2005-07-01 2012-11-13 Medimmune, Llc Integrated approach for generating multidomain protein therapeutics
PT1919503E (pt) 2005-08-10 2015-01-05 Macrogenics Inc Identificação e manipulação de anticorpos com a regiões de fc variantes e métodos de utilização dos mesmos
JP2007093274A (ja) * 2005-09-27 2007-04-12 Perseus Proteomics Inc 癌の診断方法および治療薬
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US7723043B2 (en) 2006-01-04 2010-05-25 Picobella, Lp Methods for screening for prostate cancer
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
ATE501436T1 (de) 2006-09-13 2011-03-15 Glycode Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper
WO2008046085A2 (en) 2006-10-12 2008-04-17 Supergen, Inc. Quinoline derivatives for modulating dna methylation
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
AR066172A1 (es) 2007-09-28 2009-07-29 Chugai Pharmaceutical Co Ltd Metodo para la preparacion de un anticuerpo antiglipicano 3 con modulada cinetica plasmatica mediante variacion de la semivida plasmatica.
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
TW200949248A (en) 2008-03-17 2009-12-01 Univ Miyazaki Method for detection of liver cancer cell using anti-glypican-3 antibody
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
CN101377506A (zh) * 2008-04-16 2009-03-04 北京科美东雅生物技术有限公司 磷脂酰肌醇蛋白聚糖-3化学发光免疫分析测定试剂盒及其制备方法
EP2277044B1 (en) 2008-05-13 2015-06-17 Genentech, Inc. Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry
EP2420515A4 (en) * 2009-04-16 2013-08-28 Univ Tokyo DIAGNOSIS AND TREATMENT OF CANCER WITH ANTI-TMPRSS11E ANTIBODY
CA2779281A1 (en) * 2009-11-05 2011-05-12 Malcolm A.S. Moore Catenae: serosal cancer stem cells
CN102276721B (zh) 2010-06-12 2013-12-25 上海市肿瘤研究所 一种用于肝癌血清学诊断的单克隆抗体及其用途
BR112013013354A2 (pt) 2010-11-30 2020-10-06 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente
ES2666550T3 (es) * 2011-04-19 2018-05-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos monoclonales humanos específicos para glipicano 3 y uso de los mismos
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
CN113527469A (zh) 2012-02-09 2021-10-22 中外制药株式会社 抗体的Fc区变异体
BR112014018374A8 (pt) 2012-03-02 2017-07-11 Roche Glycart Ag Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica
US9409994B2 (en) 2012-06-01 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
US9465030B2 (en) 2012-06-18 2016-10-11 National Cancer Center Kit for diagnosing malignant melanoma
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
JP5876012B2 (ja) * 2013-07-25 2016-03-02 株式会社スギノマシン 継手

Also Published As

Publication number Publication date
SG10201704963TA (en) 2017-07-28
IL239488A0 (en) 2015-08-31
JP6359461B2 (ja) 2018-07-18
KR20150096384A (ko) 2015-08-24
SG11201504604WA (en) 2015-07-30
EP2937697A4 (en) 2016-07-13
JPWO2015097928A1 (ja) 2017-03-23
CN104871003B (zh) 2019-12-20
NZ707774A (en) 2020-10-30
US10782300B2 (en) 2020-09-22
AU2013365430B2 (en) 2019-10-31
AR094269A1 (es) 2015-07-22
JP6484562B2 (ja) 2019-03-13
AU2013365430A1 (en) 2015-05-21
US20150285806A1 (en) 2015-10-08
US10451627B2 (en) 2019-10-22
RU2015129697A (ru) 2017-01-26
EP2937697B1 (en) 2019-07-03
WO2014097648A1 (ja) 2014-06-26
EP2937697A1 (en) 2015-10-28
TWI693073B (zh) 2020-05-11
IL239488B (en) 2020-08-31
MX2015007714A (es) 2015-09-07
KR102216345B1 (ko) 2021-02-17
CA2895333A1 (en) 2014-06-26
JPWO2014097648A1 (ja) 2017-01-12
RU2707882C2 (ru) 2019-12-02
US20170010270A1 (en) 2017-01-12
HK1208910A1 (en) 2016-03-18
CN111060687A (zh) 2020-04-24
CN104871003A (zh) 2015-08-26
TW201436805A (zh) 2014-10-01

Similar Documents

Publication Publication Date Title
MX376652B (es) Método para determinar la eficacia de una terapia con fármacos de direccionamiento a glipicano 3 (gpc3) contra cáncer.
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2021013880A (es) Polimeros enlazados al proton para administracion oral.
MX2015014408A (es) Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
MX2013000675A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
WO2012109022A3 (en) Medical fluid delivery device programming
MX2016005532A (es) Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades.
PH12014502738A1 (en) High-xten fusion protein and its use in the treatment of growth hormone deficiency
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
MX379191B (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
WO2011163512A3 (en) Cancer therapy
WO2014023869A3 (es) Aplicacion terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
UA88769U (uk) Спосіб профілактики та лікування доброякісних дисплазій молочних залоз у жінок з ранніми втратами вагітності
李天润 Intervention combined surgery for the treatment of acute iliofemoral vein thrombosis
张茂申 Surgical treatment and prognostic factors for obstructing left colorectal cancer
UA86411U (ru) Способ профилактики прогрессирования патологических изменений системы кровообращения у больных бронхиальной астмой

Legal Events

Date Code Title Description
FG Grant or registration